Patients
CINV, hypersensitivity, anxiety
MALIGNANT TUMOR, HYPERSENSITIVITY, ONCOLOGY
Eligible patients in the complete study were adult (≥18 years) males or females, naïve to chemotherapy, and scheduled to receive their first course of AC‐based chemotherapy or non‐AC MEC for treatment of a histologically or cytologically confirmed solid malignant tumor. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0–2. Patients were eligible if they were scheduled to receive prevention of CINV with either NEPA or an aprepitant‐based regimen (the SoC in France). Patients were ineligible if they were pregnant or breastfeeding or if they had any hypersensitivity to active substances, excipients or other ingredients of NEPA or aprepitant.Patients included in these post‐hoc analyses were (1) only those receiving MEC (not including those receiving AC) and (2) also the subset of patients receiving MEC who had a pre‐defined risk factor for developing CINV as per the protocol, i.e.: (1) female, (2) male <60 years, (3) male ≥60 years who received carboplatin, or (4) male ≥60 years with anxiety.